Download PDF
1 / Pages

Other users also viewed these articles

Perception of the impact of intravenous biological treatment on the work and professional environment in patients with inflammatory bowel disease Carlos González-Muñoza; Cristina Gely; Jordi Gordillo; Margalida Calafat; Federico Bertoletti; Fiorella Cañete; Míriam Mañosa; Alberto López-Faba; Paola Torres; Eugeni Domènech; Esther Garcia-Planella;
Gastroenterol Hepatol. 2024;47:
Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study Rodrigo Bremer Nones; Eron Fabio Miranda; Gustavo de Nardi Marçal; Fernanda da Silva Barbosa Baraúna; Marcela Rocha Loures; Paula Cenira Senger; Daniela Oliveira Magro; Paulo Gustavo Kotze;
Gastroenterol Hepatol. 2024;47:711-20
Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study Lidia Serrano Díaz; Carles Iniesta Navalón; Rosa Gómez Espín; Isabel Nicolás De Prado; Enrique Bernal Morell; Lorena Rentero Redondo;
Gastroenterol Hepatol. 2024;47:553-61